loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

RPG Life Sciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
RPG Life Sciences Ltd. 17 Oct 2025 18:14 PM
Result PDF

Q2FY26 Quarterly Result Announced for RPG Life Sciences Ltd.

Pharmaceuticals company RPG Life Sciences announced Q2FY26 results

  • Revenue from Operations: Rs 181.7 crore compared to Rs 168.9 crore during Q1FY26, change 7.6%.
  • EBITDA: Rs 43.6 crore compared to Rs 40.7 crore during Q1FY26, change 7.1%.
  • EBITDA Margin: 24.0% for Q2FY26.
  • PBT: Rs 38.2 crore compared to Rs 35.4 crore during Q1FY26, change 7.9%.
  • PAT: Rs 28.5 crore compared to Rs 26.3 crore during Q1FY26, change 8.1%.
  • PAT Margin: 15.7% for Q2FY26.

Result PDF

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q1FY26 results

  • RPG Lifesciences revenue recorded 2.1% YoY increase in sales (18.1% Q-o-Q growth) along with a healthy EBITDA margin of 24.1%.
  • Profit before tax remained largely in line with previous year stood at Rs 35.4 crore in this year vs. Rs 36.0 crore in previous year
  • Year on Year Revenue from Operations stood at Rs 168.9 crore vs. Rs 165.4 crore

Ashok Nair, Managing Director, RPG Life Sciences said, “In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach.”

“We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders,” added Nair.

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from operations: Rs 143.09 crore up from Rs 126.99 crore, Up by 13% YoY.
  • PBT before exceptional items: Rs 25.00 crore up from Rs 17.74 crore, Surges 41% YoY.

FY25 Financial Highlights:

  • Revenue from operations: Rs 653.43 crore up from Rs 582.05 crore, Up by 12% YoY.
  • PBT before exceptional items: 150.28 crore up from Rs 117.84 crore, Surges 28% YoY.
  • EBITDA Margin Expanding from 23.3% to 26.4% YoY.

Yugal Sikri, Managing Director, RPG Life Sciences, said: “In Q4FY25, the overall performance of the Company continued to be strong. Revenue and PBT before exceptional items grew by 13% and 41% respectively YoY. The full year EBITDA margin surged from 23.3% to 26.4% YoY, retaining its upward trajectory YoY for the last 6 years.

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market. Thanks to our five pillar strategy, we are building brands, portfolios and therapies; increasing sales force productivity and nurturing strategic business assets.

We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth.

Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory.

The Company has built sizeable cash surplus of ~Rs 168 crore from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to ~Rs 266 crore. We are actively pursuing inorganic opportunities to accelerate business growth.

On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 250% plus a special dividend of 50% on the face value of Rs 8 each for FY25, subject to the approval of shareholders at the ensuing Annual General Meeting, thus maintaining an upward trajectory of dividend for the last 6 years.”

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q3FY25 results

  • Revenue from operations registered a growth of 12% YoY and a flat growth QoQ for Q3FY25.
  • EBITDA Margin Jumps from 25.9% to 30.4% YoY.
  • PBT before exceptional items by 32% YoY and by 11% QoQ for Q3FY25.

Yugal Sikri, Managing Director, RPG Life Sciences. said: “In Q3FY25, the overall performance of the company continued to be strong. Revenue and PBT grew by 12% and 32% respectively YoY. EBITDA margin surged from 25.9% to 30.4% YoY retaining its upward trajectory YoY for the last more than 5 years. The Company continues to remain debtfree.

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five pillar strategy – product portfolio rejuvenation, building strategic brand/portfolio assets, sales force excellence and productivity enhancement, customer engagement through medico-marketing initiatives and continued cost efficiency drive.

We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory.

Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.”

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q1FY25 results:

Financial Highlights:

  • YoY Revenue from operations: Rs 165.42 crore – up from Rs 147.78 crore
  • YoY PBT:  Rs 36.00 crore – up from Rs 29.77 crore
  • The Company maintained an upward trajectory in EBITDA margin, which improved from 23.0% to 25.1% YoY.

Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q1FY25, the overall performance of the Company continued to be strong. Revenue and PBT grew by 12% and 21% respectively YoY. Retaining its 5-year upward trajectory, the EBITDA margin crossed the 25% mark (25.1% up from 23.0% last year).

Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market - building some of our iconic “Textbook” brands like Naprosyn into megabrands through a comprehensive life cycle management program, shaping one successful product into a multi-product portfolio by leveraging our existing strong customer franchise, building the futuristic portfolio of MABs into a formidable product segment through multibranding strategy, replicating our smart and successful Rheumatology portfolio entry strategy to enter more specialties like Gastro and Derma, and deploying digital and productivity enhancement measures to ensure consistent salesforce productivity gains year-after-year.

We are now shaping our International Formulations and API businesses to emerge as second and third growth engines.For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth and the API business is also showing promising growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory."

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue Growth: RPG Life Sciences reported a YoY revenue increase for the Q4FY24, with revenue from operations going up from Rs 118.49 crore to Rs 126.99 crore, marking a 7% growth.
  • Profit Before Tax (PBT): The company experienced a significant jump in PBT of 28% YoY for Q4FY24, climbing from Rs 13.81 crore to Rs 17.74 crore. 
  • EBITDA Margin Expansion: There has been a notable improvement in EBITDA margins, from 15% to 17.6% YoY for Q4.

FY24 Financial Highlights:

  • Revenue Growth: The full-year performance was also strong, with revenues increasing by 14% to Rs 582.05 crore for FY24, up from the previous year's Rs 512.81 crore.
  • Profit Before Tax (PBT): For the full fiscal year, PBT surged by 29%, with figures reaching Rs 117.84 crore compared to the earlier Rs 91.68 crore. 
  • EBITDA Margin Expansion: A YoY rise for the full year from 21.0% to 23.3%.

Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 7% and 28% respectively YoY. The EBITDA margin retained its 5-yearlong upward trajectory growing from 21.0% to 23.3% YoY. The Company continues to remain debt-free.

We are well on course in executing all the tenets of our distinctive and smart transformation agenda to achieve our strategic goal of consistent, healthy, and profitable growth. Our top priority, Domestic Formulations, the biggest contributor to the Company’s business, recorded robust growth in both value and volume - significantly and consistently ahead of the marketbased on its 5 pillar-growth strategy. The comprehensive smart life cycle management program is shaping some of our ‘textbook’ legacy brands into mega brands and our niche specialty portfolio into mega portfolio. New launches in specialty and chronic therapies are helping us shape our Specialty business. We are now working on replicating our smart and successful Rheumatology portfolio entry strategy to enter other specialties like Gastro and Derma to emerge as future growth drivers of Domestic Formulations business. Our MABs portfolio continues to post robust performance. Salesforce productivity continues to register healthy upward momentum, assisted by smart deployment of digital.

We are now shaping our International Formulations and API business basis their own 5 pillars, the key being plants modernization cum capacity expansion by infusion of capex and building a smart product pipeline to become strong futuregrowth drivers. The International Formulations business has been registering healthy double-digit growth. Modernization of our API Plant and building product pipeline, both currently underway, will make API also our third engine of growth.

Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain 5-year uninterrupted YoY margin expansion trajectory for the past 5 consecutive years.” 


     

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q2FY24 & H1FY24 results:

Financial Performance:
- Revenue from operations for Q2FY24 grew by 14% YoY and 4% QoQ, reaching Rs 153.58 crore.
- Revenue from operations for H1FY24 grew by 14% YoY, reaching Rs 301.36 crore.
- PBT (Profit Before Tax) for Q2FY24 grew by 29% YoY and 17% QoQ.
- PBT for H1FY24 grew by 29% YoY.
- EBITDA margins improved from 23.0% to 25.5% YoY and QoQ.
- The company remained debt-free during this period.

Domestic Formulations Business:
- The domestic formulations business, the largest contributor to the company's revenue, performed strongly.
- The business recorded robust growth in value and volume, surpassing the market growth consistently.
- Legacy brands, supported by a comprehensive life cycle management program, achieved healthy growth and became bigger brands.
- The new product portfolio in newer and progressive segments is shaping new therapies and expanding the company's product offerings.
- Foray into Rheumatology strengthened the company's Specialty segment.
- MABs portfolio posted robust performance.
- Salesforce productivity continued to register healthy upward momentum.

International Formulations Business:
- The international formulations business showed robust growth, emerging as another growth driver for the company.
- The business registered substantial growth in both sales and profits.

API Business:
- The API (Active Pharmaceutical Ingredients) business recorded healthy growth and margin improvement.

Future Plans and Initiatives:
- The company is investing in plant modernization and capacity expansion for both formulations and API.
- Focus is on building a healthy product pipeline to accelerate exports.
- Cost efficiencies in operations and sales hygiene are consistently improving margins.
- Implementation of the Transformation Agenda is on track to achieve strategic goals.

Yugal Sikri, Managing Director, RPG Life Sciences, said, “In Q2FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 14% and 29% respectively YoY. EBITDA margin retained its 5-year long upward trajectory growing from 23.0% to 25.5% YoY. The Company continues to remain debt-free.

Domestic Formulations business, the biggest contributor to the Company's business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth and become bigger brands, our new product portfolio comprising of newer and progressive segments is also shaping new therapies and product portfolio. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Salesforce productivity continues to register healthy upward momentum.

International Formulations business has also shown robust growth while emerging as another growth driver for the Company, registering healthy growth in both sales and profits. API business also registered healthy growth and improvement in margin. The Company is investing in plant modernization and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports of both formulations and API. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals."

 

 

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q4FY23 & FY23 results:

  • Q4FY23:
    • PBT up by 26% YoY for Q4FY23, maintaining the upward trajectory in EBITDA margins, which improved from 14.2% to 15.0% YoY
    • Revenue from operations at Rs 118.49 crore registered a growth of 14% YoY for Q4FY23
  • FY23:
    • For FY23, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 20.3% to 21.0% YoY
    • Revenue from operations at Rs 512.81 crore registered a growth of 17% YoY for FY23

Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4 FY23, the company maintained its upward trajectory of overall robust performance by posting yet another strong result despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 14% and 26% respectively YoY. EBITDA margins’ consistent upward trajectory has continued for the last 5 years, growing from 10.4% (FY19) to 15.9%(FY20) to 18.2% (FY21) to 20.3% (FY22) to 21.0% (FY23). The company continues to remain debt-free with the highest-ever net cashflow generated from operations in full-year FY23.

Its domestic formulations business, the biggest contributor to the company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. 

International Formulations business has also shown robust growth, while emerging as another growth driver for the company, registering healthy growth in both sales and profits. The company is investing in plant upgradation and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, are helping us to improve our margins consistently. We are well on course to implement our transformation agenda to achieve our strategic goals.”

 

Result PDF

Pharmaceuticals firm RPG Life Sciences announced Q3FY23 results:

Q3FY23 & 9MFY23:

  • RPG Life Sciences posted a jump in PBT by 25% YoY for Q3FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% YoY.
  • Revenue from operations at Rs 130.60 crores registered a growth of 13% YoY for Q3FY23. For 9MFY23 too, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 22.2% to 22.8% YoY.
  • Revenue from operations at Rs 394.32 crores registered a growth of 17% YoY for 9MFY23.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively YoY. EBITDA margin grew from 21.4% to 22.8% YoY.

Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”

 

Result PDF

Pharmaceuticals company RPG Life Sciences announced Q2FY23 results:

  • Q2FY23:
    • RPG Life Sciences posted a jump in PBT by 21% YoY and by 8% QoQ
    • EBITDA margins improved from 22.5% to 23.0% QoQ
    • Revenue from operations at Rs 134.79 crores registered a growth of 20% YoY and a growth of 5% QoQ 
  • H1FY23:
    • The company posted a jump in PBT by 25% YoY
    • EBITDA margin expanded from 22.6% to 22.8% YoY
    • Revenue from operations at Rs 263.72 crore registered a growth of 19% YoY

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2FY23, the overall performance of the Company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 20% and 21% respectively YoY. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% QoQ.

Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently ahead of market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has shown a robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations and eye on sales hygiene is helping us to consistently improve our margins. We are on course to implement our Transformation Agenda to achieve our strategic goals.”

 

 

Result PDF

Trending News

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Published on 17-Dec-2025 09:01

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL).

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL)

Published on 17-Dec-2025 09:00

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Published on 16-Dec-2025 09:05

KIMS has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Krishna Institute of Medical Sciences (KIMS) has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Published on 16-Dec-2025 09:03

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding 

Published on 16-Dec-2025 09:01

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Published on 16-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status